Marc Thill

8PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyClinical midwiferyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Sep 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt

|Sep 06, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancer.

Xiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang

|Nov 25, 2022
PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABC.

Michael Patrick Lux, Eva Diana Runkel, Esther Glastetter

|Sep 12, 2022
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).

Marc Thill, Pauline Wimberger, Andrea Grafe

|Apr 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.

Ulrike A Nitz, Oleg Gluz, Sherko Kümmel

Pageof 2

Frequent Collaborators

2 joint publications

Robert S Seitz

2 joint publications

Daniel Egle

2 joint publications

Sherko Kümmel

2 joint publications

Andreas Schneeweiss